Skip to main content
Founding Director of the Canadian Cancer Trials Group, appointed to the Order of Canada

Founding Director of the Canadian Cancer Trials Group, appointed to the Order of Canada

Dr. Joseph Pater has been recognized for a lifetime of work in cancer research with his appointment as an Officer of the Order of Canada. The honor acknowledges the impact of his dedication to clinical research which has improved the lives of Canadians with cancer.

More >>
IND.227 trial were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Results from a new study show improved survival for patients with pleural mesothelioma

Late-breaking results for the IND.227 trial were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The Phase III international study evaluated the use of the immunotherapy drug pembrolizumab combined with platinum-pemetrexed chemotherapy as a first-line treatment for pleural mesothelioma patients.

More >>
CX5 | SHAPE trial demonstrates that reduced radicality of surgical intervention can improve quality of life for patients

New study results show that simple hysterectomy is a safe option for women with early-stage, low-risk cervical cancer

A simple hysterectomy with pelvic node dissection is a safe treatment option for women with low-risk early-stage cervical cancer and may help improve quality of life, according to results from the CX5/SHAPE study, an international phase III clinical trial led by the Canadian Cancer Trials Group.

More >>
Phase III CCTG ENC1 clinical trial

Practice changing results show improved progression free survival and new treatment for patients with endometrial cancer

Practice changing data presented in endometrial cancer that demonstrates improved progression-free survival outcomes with the addition of Pembrolizumab to chemotherapy for women with advanced or recurrent endometrial cancer.

More >>

Planned trials


MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML


Master Screening and Reassessment Protocol (MYELOMATCH) for the NCI myeloMATCH clinical trials


Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)


Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)


Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy


NEEDS: NEoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed)


Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma


Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)


CALMS: Combination Therapy with Luspatercept in Lower Risk MDS


Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade Compared to Immune Checkpoint Blockade Alone in Patients with Advanced Melanoma


Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults with Newly Diagnosed Multiple Myeloma


STOPNET - Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Med-Gut Tumours


Androgen Suppression Combined with Elective Nodal Irradiation and Dose Escalated Prostate Treatment (ASCENDE-SBRT)


Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes


Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT


STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study


OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

Recently activated


Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

More >>


RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features. The MMRD-GREEN trial

More >>


PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Stage IA/IIA Hodgkin Lymphoma (RADAR)

More >>


Neoadjuvant Platform Trial in Surgically Resectable NSCLC

More >>


A Phase II Study of RP-6306 in Patients with Advanced Cancer

More >>


NET RETREAT: 177Lutetium- DOTATATE Retreatment vs. Everolimus in Metastatic/unresectable Midgut NET

More >>


The SEAMLESS Study: A randomized trial of a SmartphonE App-based MindfuLnEss intervention for cancer SurvivorS

More >>

Welcome to new Patient Representative Catherine Wreford

CCTG would like to welcome our new Patient Representative, Catherine Wreford who will be supporting the Brain Cancer Disease Site Committee. Catherine is a professional dancer and actress who was born and raised in Winnipeg, Manitoba, Canada. In 2013, a little over a month after giving birth to her second child, Catherine was diagnosed with incurable anaplastic astrocytoma (a malignant brain tumour).

More >>

Funding announced for CAR-T ethics study

A new CCTG national study has received funding from the Social Sciences and Humanities Research Council and Genome Canada to explore the ethical questions raised with emerging cancer technologies like CAR-T cell therapy.

More >>

New Patient Representative: Bill Richardson

CCTG would like to welcome Bill Richardson a new Patient Representative who will be working with the Head and Neck disease site committee. Bill is located in Calgary with a microbiologist background and has worked in government, private industry, teaching and later moved to IT spending 30 years in the Kinesiology Faculty at the University of Calgary.

More >>

Fighting a rare battle

Cancer is not a single disease; it is hundreds. Cancers of the lung, breast, prostate, and colon are the most common forms of the disease, and account for about half of all diagnoses. But less common forms of cancer also account for about half of diagnoses, and these are not as well studied.

More >>


Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients

Translational Lung Cancer Research 10: 826 - 838, 21 F
Fung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;

More >>

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

N Engl J Med 388: 2159 - 2170, 2023
Eskander RN;Sill MW;Beffa L;Moore RG;Hope JM;Musa FB;Mannel R;Shahin MS;Cantuaria GH;Girda E;Mathews C;Kavecansky J;Leath CA;Gien LT;Hinchcliff EM;Lele SB;Landrum LM;Backes F;O'Cearbhaill RE;Al Baghdadi T;Hill EK;Thaker PH;John VS;Welch S;Fader AN;Powell MA;Aghajanian C;

More >>

Salvage Radiation Therapy After Radical Prostatectomy: Analysis of Toxicity by Dose-Fractionation in the RADICALS-RT Trial (ONLINE)

International Journal of Radiation Oncology*Biology*Physics , 2023
Petersen PM;Cook AD;Sydes MR;Clarke N;Cross W;Kynaston H;Logue J;Neville P;Payne H;Parmar MKB;Parulekar W;Persad R;Saad F;Stirling A;Parker CC;Catton C;

More >>

Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial (ONLINE)

The Oncol , 2023
Gupta A;Hay AE;Crump M;Djurfeldt MS;Zhu L;Cheung MC;Shepherd LE;Chen BE;Booth CM;

More >>

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

N Engl J Med 388: 1645 - 1656, 2023
Partridge AH;Niman SM;Ruggeri M;Peccatori FA;Azim HA;Colleoni M;Saura C;Shimizu C;Sætersdal AB;Kroep JR;Mailliez A;Warner E;Borges VF;Amant F;Gombos A;Kataoka A;Rousset-Jablonski C;Borstnar S;Takei J;Lee JE;Walshe JM;Ruíz-Borrego M;Moore HCF;Saunders C;Bjelic-Radisic V;Susnjar S;Cardoso F;Smith KL;Ferreiro T;Ribi K;Ruddy K;Kammler R;El-Abed S;Viale G;Piccart M;Korde LA;Goldhirsch A;Gelber RD;Pagani O;

More >>

CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data

Cancers 15: 1823, 2023
Karamouza E;Glasspool RM;Kelly C;Lewsley LA;Carty K;Kristensen GB;Ethier JL;Kagimura T;Yanaihara N;Cecere SC;You B;Boere IA;Pujade-Lauraine E;Ray-Coquard I;Proust-Lima C;Paoletti X;

More >>

Health-related quality of life in early-stage Hodgkin lymphoma: a longitudinal analysis of the ABVD arm in the randomized controlled trial HD.6

Supportive Care in Cancer 31: 256, 2023
Mian H;Ringash J;Meyer R;Hay AE;Shepherd L;Djurfeldt M;Winter JN;Sussman J;Pater J;Chen BE;Prica A;

More >>